Slide
Securing
Connections
Corporate Profile
We are a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Our aim is alter the course of neurological diseases by advancing a pipeline of drug candidates that modulate the neurotrophic HGF system.
Minimum 15 minutes delayed. Source:
Latest Presentations
More information is coming soon.
Press Releases
November 7, 2024
October 22, 2024
Events & Presentations
September 3, 2024 at 4:30 PM EDT
June 18, 2024 at 11:30 AM EDT
June 12, 2024 at 2:00 PM EDT